Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
biotech
life sciences
national
national blog main
7
×
national top stories
new york blog main
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
clinical trials
europe blog main
fda
allergan
amgen
astrazeneca
cancer
eli lilly
europe top stories
glaxosmithkline
novartis
covid-19
What
bio
roundup
abbvie’s
acquisitions
ceo
daniel
day
days
debut
fda
gilead
labor
medicines
monday
moves
opioid
o’day
sciences
week
adults
ahead
allergan
announced
approved
august
barbecuing
biggest
biofourmis
biotech
black
bucks
build
busy
buy
camping
cancer
cardiologist
celebrate
center
chance
Language
unset
7
×
Current search:
abbvie
×
unset
×
" national blog main "
×
" new york blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More